ISRCTN15620353进行中（未招募）1 期
A Phase I study to investigate the absolute bioavailability, absorption, metabolism, distribution and excretion of [14C]AZD5363 (capivasertib) in healthy male subjects
AstraZeneca (Sweden)0 个研究点目标入组 8 人开始时间: 2022年4月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Provision of signed and dated, written informed consent prior to any study-specific procedures
- •2. Must be willing and able to communicate and participate in the whole study
- •3. Healthy males aged 30 to 65 years inclusive at the time of signing the informed consent
- •4. Must be vasectomised (at least 6 months prior to screening) and must agree to adhere to the contraception requirements
- •5. Body mass index (BMI) of 18.0 to 32.0 kg/m², weigh at least 50 kg and no more than 100 kg inclusive as measured at screening
- •6. Must have regular bowel movements (i.e. average stool production of =1 and =3 stools per day)
- •7. Provision of signed, written and dated informed consent for optional genetic research. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.
排除标准
- •1. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer’s ability to participate in the study
- •2. History of any clinically significant disease or disorder (e.g. cardiovascular, pulmonary, GI (including but not limited to refractory nausea and vomiting, malabsorption syndrome, chronic GI diseases, previous cholecystectomy, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib), liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment, skin abnormalities and glucose metabolism abnormalities) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the ADME of drugs.
- •3. History of latent or chronic infections (e.g. tuberculosis, recurrent sinusitis, genital herpes, urinary tract infections) or at risk of infection (surgery, trauma or significant infection within previous 90 days, history of skin abscesses within previous 90 days)
- •4. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP
- •5. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to capivasertib. Hay fever is allowed unless it is active.
- •6. Any known or suspected hypersensitivity or contraindication to the components of the study drug, capivasertib, judged to be clinically relevant by the investigator
- •7. History of severe COVID-19 (e.g. hospitalisation, extracorporeal membrane oxygenation, mechanically ventilated) in the last 6 months
- •8. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
- •9. Any clinically significant abnormal findings in vital signs, at screening or pre-dose, as judged by the investigator
- •10. QTcF >450 msec or QT >500 msec or other clinically significant ECG abnormality, as judged by the investigator, at screening or pre-dose, or a history of additional risk factors for Torsades de Points (e.g. heart failure, hypokalaemia, family history of long QT syndrome), which in the opinion of the Investigator may put the volunteer at risk.
- •11. Evidence of current SARS-CoV-2 infection within 2 weeks of first IMP administration
- •12. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, as judged by the investigator
- •13. Total bilirubin (TBL) =1.5 × ULN or =3 × ULN in the presence of documented Gilbert’s syndrome (unconjugated hyperbilirubinemia)
- •14. Clinically significant abnormal fasting blood glucose or triglycerides at screening
- •15. Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), and human immunodeficiency virus (HIV) 1 and 2 antibody
- •16. Evidence of renal impairment at screening, as indicated by an estimated CLcr of <70
研究者
相似试验
已完成
1 期
A study to determine the relative bioavailability of ACH-0144471 after administration of a tablet or softgel and capsule vs. a liquid filled capsule in healthy volunteers.Complement-mediated diseasesInflammatory and Immune System - Autoimmune diseasesACTRN12616001017415Achillion Pharmaceuticals Inc.26
已完成
1 期
A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy VolunteersHealthy VolunteerNCT01967966Genentech, Inc.15
进行中（未招募）
1 期
A Bioavailability Study of MK-3475A in Participants with Solid TumorsJPRN-jRCT2031220507Koh Yasuhiro96
进行中（未招募）
1 期
An exploratory study to investigate the extent to which Dupilumab becomes available to the body as well as Its actions and effects in the liquid found between the skin cells of atopic dermatitis patientsAtopic DermatitisEUCTR2018-003642-17-ATMedical University Graz8
已完成
不适用
A phase 1, open-label study to investigate the absorption, metabolism, excretion, and mass balance of [14C]pacritinib following a single oral dose in healthy male subjects.Chronic Myeloproliferative Disordersabnormal growth of blood cells in the bone marrowMyeloproliferative disordersNL-OMON41159CTI BioPharma Corporation6